Armelle Caty
Overview
Explore the profile of Armelle Caty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, et al.
JAMA Oncol
. 2019 Feb;
5(5):623-632.
PMID: 30703190
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To...
2.
Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi M, Levionnois E, et al.
Clin Cancer Res
. 2018 Aug;
24(22):5534-5542.
PMID: 30061359
The PREINSUT study characterized factors predictive of response to sunitinib given before planned nephrectomy in patients with metastatic renal cell carcinoma (mRCC). This French multicenter, prospective, open-label, phase II trial...
3.
Colomba E, Le Teuff G, Eisen T, Stewart G, Fife K, Larkin J, et al.
Eur J Cancer
. 2017 May;
80:55-62.
PMID: 28549248
Background: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of...
4.
Auvray M, Elaidi R, Ozguroglu M, Guven S, Gauthier H, Culine S, et al.
Clin Genitourin Cancer
. 2016 Dec;
15(3):e469-e476.
PMID: 27964892
Background: A high neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and is associated with poor survival in localized or metastatic cancer. This study assessed the prognostic value of...
5.
Thiery-Vuillemin A, Mouillet G, Pouessel D, Barthelemy P, Caty A, Sebbagh S, et al.
Bull Cancer
. 2014 Oct;
101(9):832-40.
PMID: 25295955
Sunitinib was the first targeted therapy improving progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) in the first line of treatment. Classically, sunitinib...
6.
Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, et al.
Acta Oncol
. 2014 May;
53(10):1413-22.
PMID: 24874929
Unlabelled: There is growing evidence that sunitinib plasma levels have an impact on treatment outcome in patients with metastatic renal cell carcinoma (mRCC). We studied the impact of single nucleotide...
7.
Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, et al.
Eur Urol
. 2013 Oct;
65(2):381-6.
PMID: 24094847
Background: Whether patients with good prognosis and intermediate/poor prognosis advanced seminoma should be treated differently has not been defined. Objective: To assess a risk-adapted chemotherapy regimen in patients with advanced...
8.
Vanhuyse M, Penel N, Caty A, Fumagalli I, Alt M, Zini L, et al.
Bull Cancer
. 2012 Dec;
99(12):100-6.
PMID: 23220100
Background: We analyzed renal cell carcinoma (RCC) brain metastasis (BM) risk factors and compared BM occurrence in metastatic RCC (mRCC) treated with or without anti-angiogenic agents (AA). Methods: Data from...
9.
Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et al.
J Clin Oncol
. 2012 Jan;
30(5):482-7.
PMID: 22231040
Purpose: Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter...
10.
Declerck L, Adenis C, Amela E, Caty A, Adenis A, Penel N
Acta Oncol
. 2011 Sep;
51(2):268-9.
PMID: 21936755
No abstract available.